# ORION (NCT03775486)

> Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

No report yet. It can be ordered.

- Indication: stage IV non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03775486
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-small Cell Lung Cancer NSCLC
- Interventions: Durvalumab; Placebo for Olaparib; Olaparib; Nab-paclitaxel+carboplatin; Gemcitabine+carboplatin; Pemetrexed+carboplatin; Gemcitabine+cisplatin; Pemetrexed+cisplatin
- Enrollment: 401
- Primary outcome: Progression-free Survival

## Indexed commentary on ORION so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=orion-nct03775486